国际资金配置仍处于历史低位附近。 年初时，DeepSeek的崛起带动"中国资产重估"，此后这一主题不再局限于科技互联网行业，中国新消费 和创新药都有所表现，而这三大主题也在今年引领了港股行情。 不过，缪子美认为，从估值角度来看，目前MSCI中国指数PE（市盈率）为11倍，PB（市净率）为1.4 倍（近10年低位）；标普500的PE为20倍以上，纳斯达克100的PE为25倍以上。可见，港股的绝对估值 处于历史低位，而美股估值处于历史高位。 同时，美股的高估值依赖于AI叙事，但盈利转化尚未完全兑现。例如，美国科技龙头ROE（净资产收 益率）为33.9%。港股科技股的动态PE（17.4倍）与盈利增速（2025年预期增长19.8%）更匹配，且AI 应用落地可能带来超预期盈利。 投行的数据显示，当前国际资金对中国的配置比例仍处于历史低位附近，但摩根士丹利近期也提及，大 多数全球投资者都明确表示，有意愿重新增配部分中国资产。 在美国资管巨头骏利亨德森投资（Janus Henderson Investors）大中华区股票负责人、基金经理缪子美 （Victoria Mio）看来，那些有创新和突破的行业企业会受重估，例如，能运 ...

买入|首次覆盖 个股表现 -40% -20% 0% 20% 40% 60% 2024-06 2024-09 2024-11 2025-01 2025-04 周大福 恒生指数 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（港元元） | 12.76 | | | | --- | --- | --- | --- | | 总股本/流通股本（亿股）99.88 | | | | | 总市值/流通市值（亿港 | 1,274.44 | | | | 元） | | | | | 52 周内最高/最低价 | 13.72 / 6.43 | | | | 资产负债率(%) | 69.8875 | | | | 市盈率 | 22.1518 | | | | Chow 第一大股东 | | Tai | Fook | | Capital Limited | | | | 研究所 分析师:李鑫鑫 SAC 登记编号:S1340525010006 Email:lixinxin@cnpsec.com 证券研究报告：纺织服饰 | 公司点评报告 发布时间：2025-06-22 股票投资评级 周大福 (1929.HK) 产品结构优化，同店逐季改善 ⚫ 事 ...

Core Viewpoint - A lawsuit has been filed against Compass Diversified Holdings and its executives for potential violations of federal securities laws, specifically related to alleged misstatements in financial reporting [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Matthews v. Compass Group Diversified Holdings, Inc., et al., No. 25-cv-981 [2]. - Investors who purchased Compass securities are encouraged to seek additional information and may have until July 8, 2025, to request to lead the case [2]. Group 2: Allegations Against Compass - The complaint alleges that Compass's fiscal 2024 financial statements contained material misstatements regarding unrecorded financing arrangements and irregularities in sales, cost of sales, inventory, and accounts receivable related to Lugano Holdings, Inc. [3]. - Compass is a statutory trust that manages a portfolio of small and middle-market businesses, including Lugano Holdings, a high-end jewelry designer and manufacturer [3]. Group 3: Stock Market Reaction - Following the announcement on May 7, 2025, that investors should not rely on its fiscal 2024 financial statements due to an ongoing internal investigation, Compass's stock price fell approximately 62%, from $17.25 per share to $6.55 per share [4]. - The company indicated that it had identified irregularities in Lugano's financing, accounting, and inventory practices, leading to the resignation of Lugano's founder and CEO without severance compensation [4].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and certain senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and investors have until July 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health and has historically provided a healthy dividend to its shareholders [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased the company's debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant cut in the dividend [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may request to be appointed to lead the case by July 11, 2025 [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused the review of Medicaid eligibility during COVID-19, which resumed in 2023, leading to increased scrutiny of Medicaid members [3]. Group 3: Allegations of Misrepresentation - Elevance allegedly misrepresented its monitoring of cost trends associated with the Medicaid redetermination process and the sufficiency of negotiated rates to address patient risk profiles [4]. - The redetermination process reportedly caused a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 4: Stock Price Impact - Following Elevance's announcement on July 17, 2024, regarding increased Medicaid utilization, the stock price fell by $32.21 per share, nearly 6%, from $553.14 to $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61 per share, nearly 11%, from $496.96 to $444.35 [7].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs in driving demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, attributing the poor performance to slow treatment timelines and high patient drop-off rates [5]. Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial performance and operational challenges [6].

剥离欧洲包袱尘埃落定，经营质量大幅改善 根据公告，2025年上半年宁波华翔的归母净利润为亏损2.73亿元至3.69亿元，主要源自对六家欧洲子公司剥离的一次性影响。但从可持续经营角度 来看，公司主业保持良好韧性，扣非净利润达4.95亿元至5.91亿元，同比稳健增长。 早在2024年年报中，宁波华翔已明确提出"海外减负"的战略。此次与德国Mutares完成交易后，公司多年的资源占用和盈利压力被基本清除，整体 利润结构更加清晰健康。 值得注意的是，宁波华翔并未"永久告别"欧洲市场，而是以"暂别"姿态为将来在条件成熟时的战略性回归预留空间。在现金流与管理资源显著释 放后，公司得以将重心转回国内核心客户和高成长赛道，推动新旧动能有序切换。 自主品牌持续放量，从"0到1"加速迈向"1到10" （原标题：宁波华翔上半年扣非预计增长5.25%至25.73% 转型提速促进盈利能力改善） 6月20日晚，宁波华翔(002048)发布2025年半年度业绩预告称，公司扣非净利润同比增长5.25%至25.73%，展现出核心业务盈利能力的显著增强和 转型成效的逐步兑现。这一数据不仅标志着长期困扰宁波华翔业绩表现的欧洲业务"包袱"正式落地清 ...

中新网重庆6月22日电杜伊斯堡消息：当地时间21日上午，中欧班列+西部陆海新通道东盟快班推介活 动在德国杜伊斯堡DIT场站及渝新欧海外仓举行。来自中、德、法等国家铁路运营方、企业、国际货运 代理等代表，围绕"欧亚双向联通共创发展机遇"主题共谋合作大计、共商未来发展。 "东盟快班核心创新在于实现了中欧班列与西部陆海新通道的双通道联动，通过资源整合打破区域壁 垒，构建起欧亚经贸合作新桥梁。"陆海新通道运营有限公司董事长，渝新欧(重庆)供应链管理有限公 司执行董事、总经理刘太平表示，东盟快班在全链运输、时效、费用等多方面均具有明显优势。今年内 还将打造"中土快线"，进一步提升由重庆跨里海经土耳其中转的中欧班列南通道服务。 "东盟快班的开行，进一步推动中南半岛通过中国与欧洲联通。"老挝国家工商会中老商务合作促进委员 会副会长郑志盛说，相信东盟快班将为区域合作注入强大动力，也将为众多合作伙伴带来更加广阔的市 场前景。 活动现场，与会代表分别围绕重庆市现代生产性服务业发展规划和投资机会、东盟快班线路产品、通道 合作经验以及通道金融服务进行专题推介及分享交流，进一步为中德企业提供高效、低成本的国际物 流、金融解决方案，围绕 ...

转自：草原云 内蒙古羊肉名扬天下，如今羊奶也能"点石成金"。 内蒙古巴彦淖尔"80后"创业者郝志伟用新鲜的羊奶以及洋甘菊、青蒿等药材制作成羊乳洁面皂，以独特 的技艺赢得大众的青睐，在2025北京国际文旅消博会上演绎着传统产业的绿色新生。 向参观者介绍内蒙古特色产品。 "制作羊奶皂需要多种中药材，之前都是去外地药材市场采购，这就增加了制作成本。"内蒙古哆啦文化 发展有限公司负责人郝志伟介绍，"这个创新产品，背后是产学研的深度结合。我们在乌拉特中旗种植 洋甘菊、青蒿等药材，一部分用来做羊奶皂原料，一部分由上海药企进行销售，这既降低成本又帮助农 牧民增加收入。" 琳琅满目的内蒙古好物。 6月20日至22日，在2025北京国际文旅消博会上，郝志伟带来的羊奶皂一亮相，就引起参展商和消费者 关注。"通过参加这次消博会，凭借'首都+国际'的双重属性，不仅让我们展示了技艺，吸引了国内外客 户，更为企业发展积累认知、资源和品牌势能。"郝志伟说。 同样，在此次消博会内蒙古展区，来自鄂尔多斯铜川镇的沙棘原浆汁"吸睛"无数，参观者对独特的酸爽 味赞不绝口。 参观者品鉴沙棘原浆汁。 "这是我们村集体经济打造的特色农品'天骄常青'沙棘原 ...

计算机 证券研究报告 | 行业周报 gszqdatemark 2025 06 22 年 月 日 增持资维持） 行业走势 作者 -20% 0% 20% 40% 60% 80% 2024-06 2024-10 2025-02 2025-06 计算机 沪深300 分析师 刘高畅 执业证书编号：S0680518090001 邮箱：liugaochang@gszq.com 分析师 杨然 执业证书编号：S0680518050002 邮箱：yangran@gszq.com 相关研究 1、《计算机：Coding 驱动全球 AI 应用闭环》 2025-06- 14 全球稳定币竞争加速 6 月 20 日，中国人民银行和香港金融管理局发布联合公告，中国人民银 行与香港金管局公布，将推出"跨境支付通"，人民币国际化进程会由此 迈出新一步。 香港稳定币政策快速推进、诸多领域巨头竞相角逐。诸多巨头参与香港稳 定币角逐：内地的互联网资本入围首批沙盒测试的京东；已经明确表态申 请意图的蚂蚁集团；入围首批沙盒测试的圆币创新；第四方则来自香港本 土，如渣打香港、Web3 企业安拟集团与香港电讯共同构成。1）京东：6 月 17 日，京东集团董事局 ...